ALX-1393

ALX-1393^[1]
Names
	IUPAC name (2S)-2-Amino-3-[(3-fluorophenyl)-(2-phenylmethoxyphenyl)methoxy]propanoic acid
Identifiers
CAS Number	949164-09-4;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL475562;
ChemSpider	115042561;
IUPHAR/BPS	4622;
PubChem CID	16078939;
	InChI InChI=1S/C23H22FNO4/c24-18-10-6-9-17(13-18)22(29-15-20(25)23(26)27)19-11-4-5-12-21(19)28-14-16-7-2-1-3-8-16/h1-13,20,22H,14-15,25H2,(H,26,27)/t20-,22?/m0/s1 Key: ADUSZEGHFWRTQS-AIBWNMTMSA-N;
	SMILES C1=CC=C(C=C1)COC2=CC=CC=C2C(C3=CC(=CC=C3)F)OCC(C(=O)O)N;
Properties
Chemical formula	C23H22FNO4
Molar mass	395.430 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

ALX-1393 is a glycine reuptake inhibitor.

Pharmacodynamics

ALX-1393 works by inhibiting the action of GLYT2.^[2] This causes elevated levels of glycine, an inhibitory neurotransmitter.

Potential uses

ALX-1393 has been shown to have potential as an analgesic. This is thought to be due to the elevated glycine levels reducing the transmission of the pain signals.^[3]

Tests have shown that it was able to help reduce cancer pain in a potent way.^[4]

References

↑ "(2S)-2-amino-3-{[2-(benzyloxy)phenyl](3-fluorophenyl)methoxy}propanoic acid".
↑ Eckle, V.-S.; Antkowiak, B. (2013-12-03). "ALX 1393 inhibits spontaneous network activity by inducing glycinergic tonic currents in the spinal ventral horn". Neuroscience. 253: 165–171. doi:10.1016/j.neuroscience.2013.08.042. ISSN 1873-7544. PMID 23994185. S2CID 30039776.
↑ Benito-Muñoz, Cristina; Perona, Almudena; Felipe, Raquel; Pérez-Siles, Gonzalo; Núñez, Enrique; Aragón, Carmen; López-Corcuera, Beatriz (2021-06-02). "Structural Determinants of the Neuronal Glycine Transporter 2 for the Selective Inhibitors ALX1393 and ORG25543". ACS Chemical Neuroscience. 12 (11): 1860–1872. doi:10.1021/acschemneuro.0c00602. ISSN 1948-7193. PMC 8691691. PMID 34003005.
↑ Motoyama, Naoyo; Morita, Katsuya; Shiraishi, Seiji; Kitayama, Tomoya; Kanematsu, Takashi; Uezono, Yasuhito; Dohi, Toshihiro (October 2014). "Relief of cancer pain by glycine transporter inhibitors". Anesthesia and Analgesia. 119 (4): 988–995. doi:10.1213/ANE.0000000000000388. ISSN 1526-7598. PMID 25076101.

This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "(2S)-2-amino-3-{[2-(benzyloxy)phenyl](3-fluorophenyl)methoxy}propanoic acid".

[2] Eckle, V.-S.; Antkowiak, B. (2013-12-03). "ALX 1393 inhibits spontaneous network activity by inducing glycinergic tonic currents in the spinal ventral horn". Neuroscience. 253: 165–171. doi:10.1016/j.neuroscience.2013.08.042. ISSN 1873-7544. PMID 23994185. S2CID 30039776.

[3] Benito-Muñoz, Cristina; Perona, Almudena; Felipe, Raquel; Pérez-Siles, Gonzalo; Núñez, Enrique; Aragón, Carmen; López-Corcuera, Beatriz (2021-06-02). "Structural Determinants of the Neuronal Glycine Transporter 2 for the Selective Inhibitors ALX1393 and ORG25543". ACS Chemical Neuroscience. 12 (11): 1860–1872. doi:10.1021/acschemneuro.0c00602. ISSN 1948-7193. PMC 8691691. PMID 34003005.

[4] Motoyama, Naoyo; Morita, Katsuya; Shiraishi, Seiji; Kitayama, Tomoya; Kanematsu, Takashi; Uezono, Yasuhito; Dohi, Toshihiro (October 2014). "Relief of cancer pain by glycine transporter inhibitors". Anesthesia and Analgesia. 119 (4): 988–995. doi:10.1213/ANE.0000000000000388. ISSN 1526-7598. PMID 25076101.

[1]

[2]

[3]

[4]